Chimp Check: NIH Seeks Input on Primate Research Paperwork
Published Date: 2/19/2026
Notice
Summary
The NIH wants to keep using a form that helps them check if chimpanzee research follows their rules. They’re asking the public to share thoughts by April 20, 2026, to make sure the form is useful and not too much work. This won’t cost extra money but helps keep research safe and fair for chimps and scientists alike.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Funding Limited to Noninvasive Research
The NIH will not fund any research involving chimpanzees proposed in new or other competing projects unless the research is consistent with the definition of "noninvasive research" in the "Standards of Care for Chimpanzees Held in the Federally Supported Chimpanzee Sanctuary System" (42 CFR part 9). Researchers proposing chimpanzee studies must use the Chimpanzee Research Use Form and meet that noninvasive standard before NIH will consider funding or allow the research to begin.
Mandatory Chimpanzee Form Extended
The NIH is seeking to extend the Chimpanzee Research Use Form (OMB control 0925-0705) and asks for public comments by April 20, 2026. Completing the form is mandatory to receive NIH support for noninvasive chimpanzee research, OMB approval is requested for three years, and the agency estimates a total annual burden of 15 hours for 30 respondents (about 0.5 hours per response). There are no costs to respondents other than their time.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2026-03213, Determination That TOLECTIN DS (Tolmetin Sodium) Capsule, Equivalent to 400 Milligrams Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOLECTIN DS (tolmetin sodium) 400 mg capsules weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back!
Next: 2026-03215, Establishment of Department of War Federal Advisory Committee-Science, Technical, and Innovation BoardF
The Department of War is creating a new Science, Technology, and Innovation Board (STIB) to combine and replace two older advisory groups. This fresh board will help guide the department on cool tech and innovation stuff, starting early 2026. If you’re interested, you can send in your ideas anytime, and this change aims to streamline advice without extra costs.